Blue Label impairs Cell C investment to nil for year end, is it time to buy?

PUBLISHED: Thu, 19 Sep 2019 16:27:48 GMT


With both Net1 & Blue Label impairing their Cell C investment to nil for their year ends, CNBC Africa’s Fifi Peters asked Henry Biddlecombe, an Analyst at Anchor Capital, whether he would be buying Blue Label?

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.